Antibody To Inhibit Inflammasome Activation

Brief Description

A monoclonal antibody that selectively targets the NLRP3 pyrin domain to inhibit inflammasome activation in inflammasome-related diseases.

Full Description

This innovative monoclonal antibody specifically binds to the NLRP3 pyrin domain, preventing its interaction with oxidized DNA, a critical step in inflammasome activation within macrophages. Unlike existing solutions that target the NLRP3 NACHT domain or inhibit IL-1β receptors downstream, this approach offers targeted inhibition with reduced off-target effects, preserving other immune responses. The antibody has demonstrated significant inflammasome activation reduction in cellular models, marking a novel therapeutic strategy for inflammasome-mediated diseases.

Suggested uses

• Treatment of inflammasome-related diseases and disorders. 
• Pharmacological management of autoimmune and inflammatory conditions. 
• Development of targeted biologics for precision immunotherapy. 
• Use in research and drug discovery focused on inflammasomes.

Advantages

• Selective targeting of the NLRP3 pyrin domain avoids off-target effects seen with NACHT domain inhibitors. 
• Prevents interaction between NLRP3 and oxidized DNA, a novel mechanism of action. 
• Maintains immune responsiveness to other inflammasomes and danger signals. 
• Demonstrated substantial inflammasome inhibition in vitro. 
• Potential for improved safety and efficacy over current IL-1β receptor inhibitors

Related Materials

• Cabral, A., et al. McNulty, R. (2023). Differential binding of NLRP3 to non-oxidized and ox-mtDNA mediates NLRP3 inflammasome activation. Commun. Biol., 6.
• RM1mAb avoids Intracellular degradation to Synergistically inhibit NLRP3 Inflammasome Activation in Familial Cold Autoinflammatory Syndrome. Angela Lackner, Sofia I. Picucci, Valerie Henriquez, Karen Wang, Reginald McNulty bioRxiv 2025.12.09.693294